Abvc Biopharma (ABVC) Current Leases (2019 - 2026)

Abvc Biopharma (ABVC) has reported Current Leases for 8 consecutive years, with $358107.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases rose 26.9% year-over-year to $358107.0; the trailing twelve-month figure through Jun 2026 stood at $358107.0 (up 26.9% YoY), and the FY2025 full-year result was $317557.0, down 21.32% from the prior year.
• Current Leases grew to $358107.0 in Q2 2026 per ABVC's latest filing, from $332252.0 in the prior quarter.
• Across five years, Current Leases topped out at $403581.0 in Q4 2024 and bottomed at $199335.0 in Q3 2025.
• Historically, Current Leases has averaged $355428.6 across 5 years, with a median of $365966.5 in 2024.
• The sharpest annual moves came in 2025 and 2026: Current Leases slumped 45.46% in 2025, then gained 26.9% in 2026.
• Over 5 years, Current Leases stood at $369314.0 in 2022, then climbed by 8.8% to $401826.0 in 2023, then advanced by 0.44% to $403581.0 in 2024, then decreased by 21.32% to $317557.0 in 2025, then grew by 12.77% to $358107.0 in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $358107.0, $332252.0, and $317557.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.